Compare SNOA & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOA | XAIR |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.4M |
| IPO Year | 2006 | 2015 |
| Metric | SNOA | XAIR |
|---|---|---|
| Price | $1.12 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 93.8K | ★ 330.7K |
| Earning Date | 02-10-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,288,000.00 | $3,705,000.00 |
| Revenue This Year | $23.00 | $122.00 |
| Revenue Next Year | $24.59 | $58.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.19 | ★ 219.67 |
| 52 Week Low | $1.80 | $0.15 |
| 52 Week High | $6.92 | $3.78 |
| Indicator | SNOA | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 26.78 | 35.12 |
| Support Level | N/A | $0.43 |
| Resistance Level | $3.84 | $0.82 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 14.19 | 19.85 |
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.